Dyne Therapeutics Inc Aktie News

- DYNE-302 Demonstrated Functional Improvement in an FSHD Preclinical Model - WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) --  Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that it will be presenting new preclinical data demonstrating the pote...

- FDA (CDER) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following receipt of meeting minutes -

- Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned for late 2025 - WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people livin...

- Vikram Ranade, PhD, appointed as chief business officer - - Ranjan Batra, PhD, appointed as chief scientific officer - - Oxana Beskrovnaya, PhD, transitioning to chief innovation officer - WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driv...

WALTHAM, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to three new employees. The awards were approved by Dyne's Compensation Committee and made as an induce...

WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced it has granted inducement equity awards to its newly appointed Chief Financial Officer, Erick J.

- Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation -

- Continued favorable safety profile for DYNE-251 - - DELIVER Registrational Expansion Cohort is fully enrolled;  data from this cohort planned for late 2025 - - Potential for Biologics License Application submission for U.S. accelerated approval  in early 2026 - WALTHAM, Mass., March 16, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advanci...